|Mr. Michael S. Weiss Esq.||Chairman, CEO & Pres||1.63M||N/A||1966|
|Mr. Sean A. Power CPA, CPA||CFO, Corp. Sec. & Treasurer||509.54k||N/A||1982|
|Dr. Owen A. O'Connor||Chief Scientific Officer||N/A||N/A||N/A|
|Jenna Bosco||Sr. VP of Corp. Communications||N/A||N/A||N/A|
|Mr. Adam Waldman||Chief Commercialization Officer||N/A||N/A||N/A|
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. The company is headquartered in New York, New York.
TG Therapeutics, Inc.’s ISS governance QualityScore as of 26 September 2021 is 10. The pillar scores are Audit: 9; Board: 10; Shareholder rights: 4; Compensation: 10.